Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory for Molecular Medicine, |
RCV000214849 | SCV000271349 | pathogenic | Rare genetic deafness | 2015-11-24 | criteria provided, single submitter | clinical testing | The p.Cys542Phe variant in COCH has been reported in one family with post-lingua l progressive sensorineural hearing loss, in which the variant segregated with h earing loss in 15 affected relatives in an autosomal dominant pattern (Street 20 05). In addition, this variant was absent from large population studies and two other variants (p.Cys542Arg, p.Cys542Tyr) affecting the same position have also been reported in families with dominant hearing loss (Yuan 2008, Tsukada 2015) i ndicating that this position is intolerant to variation. In summary, this varian t meets our criteria to be classified as pathogenic for hearing loss in an autos omal dominant manner based on segregation data and absence in controls. |
Gene |
RCV001547940 | SCV001767763 | pathogenic | not provided | 2022-12-06 | criteria provided, single submitter | clinical testing | Reported by exome sequencing in a proband with mild bilateral sensorineural hearing loss, but age-of-onset and segregation information were not provided (Sheppard et al., 2018); This variant was found significantly more frequently in cases with ICD10 codes for hearing loss vs. controls in a large association study; the authors suggested that the presence in the two controls may be explained by either imperfect ascertainment of the phenotype or variable expressivity (Praveen et al., 2022); A meta-analysis on published cases with variants in the COCH gene suggested that p.C542F was associated with an earlier age-of-onset than the other variants evaluated based on non-linear regression analysis of audiometric data (Robijn et al., 2022); Published functional studies demonstrate a damaging effect: reduced binding affinity to N-sulfated heparin (Honda et al., 2022); Not observed in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 16261627, 35901072, 35661827, 29907799, 35204720) |
Labcorp Genetics |
RCV001547940 | SCV002237040 | pathogenic | not provided | 2024-12-06 | criteria provided, single submitter | clinical testing | This sequence change replaces cysteine, which is neutral and slightly polar, with phenylalanine, which is neutral and non-polar, at codon 542 of the COCH protein (p.Cys542Phe). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with autosomal dominant deafness (PMID: 16261627). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 6614). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt COCH protein function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects COCH function (PMID: 16261627). For these reasons, this variant has been classified as Pathogenic. |
Pittsburgh Clinical Genomics Laboratory, |
RCV000006993 | SCV005397658 | pathogenic | Autosomal dominant nonsyndromic hearing loss 9 | 2023-11-17 | criteria provided, single submitter | clinical testing | This sequence variant is a single nucleotide substitution (G>T) at position 1625 of the coding sequence of the COCH gene that results in a cysteine to phenylalanine amino acid change at residue 542 of the cochlin protein. This residue is part of a structural disulfide bond (PMID: 16261627). This is a previously reported variant (ClinVar 6614) that has been observed segregating with progressive hearing loss in all affected members of a large family (PMID: 16261627). This variant is absent from the gnomAD population database (0/~152000 alleles). Multiple bioinformatic tools predict that this cysteine to phenylalanine amino acid change would be damaging, and the Cys542 residue at this position is highly conserved across the vertebrate species examined. Studies examining the functional consequence of this variant have demonstrated that post-translational proteolytic processing is altered (PMID: 16261627), and the variant protein has a decreased affinity for heparin (PMID: 35901072). Based upon the evidence, we consider this variant to be pathogenic. ACMG Criteria: PM2, PP1, PP3, PS3, PS4 |
OMIM | RCV000006993 | SCV000027189 | pathogenic | Autosomal dominant nonsyndromic hearing loss 9 | 2005-12-01 | no assertion criteria provided | literature only | |
Division of Human Genetics, |
RCV000006993 | SCV000536925 | likely pathogenic | Autosomal dominant nonsyndromic hearing loss 9 | 2016-02-29 | no assertion criteria provided | research |